President Donald Trump said the University of Miami has given the federal government its original 1994 ibogaine Investigational New Drug application.
The application will give “everyone direct access to the foundational FDA authorization to accelerate its development as a medical treatment in the U.S.,” according to an Aug. 18 post on Truth Social.
President Trump signed an executive order in April to accelerate medical treatments for serious mental illness, including psychedelic drugs and ibogaine.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
